Merck & Co., Inc. (MRK) Tops Q3 EPS by 3c
Tweet
Share
E-mailGet Alerts MRK Hot Sheet
Price: $152.20 +12.60%
Financial Fact:
Research and development: 5.14B
Today's EPS Names:
JAGX, CLIR, ZTO, More
Financial Fact:
Research and development: 5.14B
Today's EPS Names:
JAGX, CLIR, ZTO, More
Join SI Premium – FREE
Merck & Co., Inc. (NYSE: MRK) reported Q3 EPS of $0.94, $0.03 better than the analyst estimate of $0.91. Revenue for the quarter came in at $12 million versus the consensus estimate of $11.61 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Morgan Stanley Upgrades Merck (MRK) to Overweight
- Moderna shares soar on melanoma drug trial success
- William Blair Upgrades Moderna (MRNA) to Outperform, 'we believe Moderna has a clear line of sight to revenue diversification from the COVID business
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
